Page 1

/// Release Savara Reports Third Quarter 2021 Financial Results and Provides Business Update AUSTIN , Texas -- ( BUSINESS WIRE ) -- Nov . 12 , 2021-- ( Nasdaq : SVRA ) , a clinical stage biopharmaceutical company focused on rare respiratory diseases , today reported financial results for the third quarter ending September 30 , 2021 and provided a business update . " The team is focused and driving hard on advancing the pivotal Phase 3 IMPALA 2 trial , ” said Matt Pauls , Chair and Chief Executive Officer , Savara . “ Given that an increasing number of sites are actively screening and enrolling patients , and we completed an important regulatory milestone with EMA's acceptance of our proposed revised PIP , we are pleased with our progress over the last quarter . While the potential impact of COVID - 19 and the flu over the winter is unknown , we remain confident in our guidance of a 20 - month enrollment timeframe and top- line data by the end of Q2 2024. Finally , we significantly bolstered our inhalation delivery and biological product expertise in the manufacturing , regulatory , and quality functions with the addition of Peter Clarke and Charles LaPree . " Third Quarter Financial Results ( Unaudited ) Savara's net loss attributable to common stockholders for the three months ended September 30 , 2021 , was $ 10.5 million , or $ ( 0.07 ) per share , compared with a net loss attributable to common stockholders of $ 11.1 million , or $ ( 0.18 ) per share , for the three months ended September 30 , 2020 . Research and development expenses increased by $ 0.9 million , or 16.6 % , to $ 6.5 million for the three months ended September 30 , 2021 from $ 5.6 million for the three months ended September 30 , 2020. The increase was primarily attributable to an approximately $ 3.2 million increase in costs associated with the screening of patients and progression of the IMPALA - 2 trial for the molgramostim development program . This was partially offset by a $ 2.1 million decrease in chemistry , manufacturing , and control ( " CMC " ) and clinical operations activities associated with the wind down of the vancomycin study in methicillin - resistant ( MRSA ) lung infection . General and administrative expenses decreased by $ 2.0 million , or 36.7 % , to $ 3.4 million for the three months ended September 30 , 2021 from $ 5.4 million for the three months ended September 30 , 2020. The decrease was primarily due to the recognition of a one - time non - recurring charge